Astrazeneca (AZN) Equity Income (2014 - 2026)

Astrazeneca (AZN) has reported Equity Income for 13 consecutive years, with -$12.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Income fell 71.43% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$12.0 million (up 45.45% YoY), while the FY2025 annual figure was -$7.0 million, up 75.0% from the prior year.
• Equity Income came in at -$12.0 million for Q1 2026 at Astrazeneca, down from $10.0 million in the prior quarter.
• The five-year high for Equity Income was $10.0 million in Q3 2025, with the low at -$13.0 million in Q1 2024.
• Average Equity Income over 5 years is -$3.7 million, with a median of -$4.5 million recorded in 2024.
• Across the five-year window, Equity Income plunged 1200.0% in 2023 and surged 350.0% in 2025, its largest moves.
• Year by year, Equity Income stood at -$1.0 million in 2022, then slumped by 1000.0% to -$11.0 million in 2023, then soared by 54.55% to -$5.0 million in 2024, then surged by 300.0% to $10.0 million in 2025, then plunged by 220.0% to -$12.0 million in 2026.
• According to Business Quant data, Equity Income over the past three periods registered -$12.0 million, $10.0 million, and -$10.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.